Article
Integrase inhibitors in the treatment of HIV-1 infection
18 Sept 2010
Abstract excerpt
Agents active against HIV type 1 (HIV-1) that target the viral integrase by inhibiting the strand transfer step of integration have now entered the clinical arena. Raltegravir is the first in this new class. Clinical trials in treatment-experienced and in treatment-naive patients have shown that raltegravir-containing regimens have potent antiretroviral activity and are well tolerated. Drug resistance emerges...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
